We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Clinical Dentistry

Journal Scan / Research · September 11, 2022

Inferior Alveolar Nerve Block Success of 2% Mepivacaine vs 4% Articaine in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars

International Endodontic Journal


Additional Info

Disclosure statements are available on the authors' profiles:

International Endodontic Journal
Inferior alveolar nerve block success of 2% mepivacaine versus 4% articaine in patients with symptomatic irreversible pulpitis in mandibular molars: A randomized double-blind single-centre clinical trial
Int Endod J 2022 Aug 10;[EPub Ahead of Print], MFOM Habib, S Tarek, SME Teama, K Ezzat, RM El Boghdadi, A Marzouk, MY Fouda, SI Gawdat, MM Bedier, SAW Amin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading